BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

At 3.5 Years, 83% of Patients on BLINCYTO Plus Chemotherapy Were Alive Versus 65% of Patients on Chemotherapy Alone Trial Design and Conduct Sponsored by the ECOG-ACRIN Cancer Research Group THOUSAND OAKS, Calif., Dec. 13, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the...

Click to view original post